Immunotherapy in Collagen-Induced Arthritis: Past, Present, and Future

American Journal of the Medical Sciences

Volumn 327, Issue 4, 2004, Pages 217-226

  Wooley, Paul H ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Biological response modifiers; Collagen induced arthritis; Cytokines; Drugs; Immunotherapy

Indexed keywords

AUTACOID; BIOLOGICAL RESPONSE MODIFIER; COLLAGEN TYPE 2; CYTOKINE; ETANERCEPT; HYBRID PROTEIN; IMMUNOGLOBULIN G; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 12; INTERLEUKIN 12 ANTAGONIST; INTERLEUKIN 2 RECEPTOR BLOCKING AGENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 7D4; MONOCLONAL ANTIBODY F23.1; MONOCLONAL ANTIBODY GK1.5; POLYCLONAL ANTIBODY; PROTEIN P40; PROTEIN P55; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG;

ANTIGEN RECOGNITION; ARTHROPATHY; AUTOIMMUNITY; CELL TRANSFER; CLINICAL FEATURE; COLLAGEN INDUCED ARTHRITIS; CONFERENCE PAPER; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; GENE THERAPY; GENE TRANSFER; HYBRIDOMA; IMMUNOTHERAPY; JOINT DESTRUCTION; LYMPHOCYTE MIGRATION; NONHUMAN; PATHOGENESIS; RHEUMATOID ARTHRITIS; SIGNAL DETECTION; SIGNAL TRANSDUCTION; SYNOVIUM; T LYMPHOCYTE SUBPOPULATION;

EID: 1842683020     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200404000-00008     Document Type: Conference Paper

References (78)

1. Courtenay JS, Dallman MJ, Dayan AD, et al. Immunisation against heterologous type II collagen induces arthritis in mice. Nature 1980;283:666-8.
2. Wooley PH, Luthra HS, Stuart JM, et al. Type II collagen-induced arthritis in mice. I. Major histocompatibility complex (I region) linkage and antibody correlates. J Exp Med 1981;154:688-700.
3. Holmdahl R, Karlsson M, Andersson ME, et al. Localization of a critical restriction site on the I-A beta chain that determines susceptibility to collagen-induced arthritis in mice. Proc Nat Acad Sci U S A 1989;86:9475-9.
4. Wooley PH, Luthra HS, Singh SK, et al. Passive transfer of arthritis to mice by injection of human anti-type II collagen antibody. Mayo Clin Proc 1984;59:737-43.
5. Phadke K, Fouts RL, Parrish JE, et al. Evaluation of the effects of various anti-arthritic drugs on type II collagen-induced mouse arthritis model. Immunopharmacology 1985;10:51-60.
6. Stuart JM, Myers LK, Townes AS, et al. Effect of cyclophosphamide, hydrocortisone and levamisole on collagen-induced arthritis in rats. Arthritis Rheum 1981;24:790-4.
7. McCune WJ, Trentham DE, David JR. Gold does not alter the arthritic, humoral, or cellular responses in rats with type II collagen-induced arthritis. Arthritis Rheum 1980;23:932-6.
8. Cannon GW, McCall S, Cole BC, et al. Effects of indomethacin, cyclosporin, cyclophosphamide, and placebo on collagen-induced arthritis of mice. Agents Actions 1990;29:315-23.
9. Takagishi K, Kaibara N, Hotokebuchi T, et al. Effects of cyclosporin on collagen induced arthritis in mice. Ann Rheum Dis 1986;45:339-44.
10. Kaibara N, Hotokebuchi T, Takagishi K, et al. Paradoxical effects of cyclosporin on collagen arthritis in rats. J Exp Med 1983;158:2007-18.
11. Arita C, Hotokebuchi T, Miyahara H, et al. Inhibition by FK506 of established lesions of collagen-induced arthritis in rats. Clin Exp Immunol 1990;82:456-61.
12. Inamura N, Hashimoto M, Nakahara K, et al. Immunosuppressive effect of FK506 on collagen-induced arthritis in rats. Clin Immunol Immunopathol 1988;46:82-90.
13. Helfgott SM, Bazin H, Dessein A, et al. Suppressive effects of anti-mu serum on the development of collagen arthritis in rats. Clin Immunol Immunopathol 1984;31:403-11.
14. Brahn E, Trentham DE. Effect of antithymocyte serum on collagen arthritis in rats: evidence that T cells are involved in its pathogenesis. Cell Immunol 1984;86:421-8.
15. Griffiths MM. Immunogenetics of collagen-induced arthritis in rats. Int Rev Immunol 1988;4:1-15.
16. Wooley PH, Chapdelaine JM. Immunogenetics of collagen-induced arthritis. [review]. CRC Crit Rev Immunol 1987;8:1-22.
17. Wooley PH, Luthra HS, Lafuse WP, et al. Type II collagen-induced arthritis in mice. III. Suppression of arthritis by using monoclonal and polyclonal anti-Ia antisera. J Immunology 1985;134:2366-74.
18. Ranges GE, Sriram S, Cooper SM. Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4. J Exp Med 1985;162:1105-10.
19. Goldschmidt TJ, Andersson M, Malmstrom V, et al. Activated type II collagen reactive T cells are not eliminated by in vivo anti-CD4 treatment. Implications for therapeutic approaches on autoimmune arthritis. Immunobiology 1992;184:359-71.
20. Kirstein H, Hjarvard K, Hansen TM. Antikeratin antibodies in synovial fluid in rheumatoid arthritis. Acta Pathol Microbiol Immunol Scand 1989;97:185-9.
21. Moreland LW, Bucy RP, Tilden A, et al. Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis. Arthritis Rheum 1993;36:307-18.
22. Levitt NG, Fernandez-Madrid F, Wooley PH. Pristane induced arthritis in mice. IV. Immunotherapy with monoclonal antibodies directed against lymphocyte subsets. J Rheumatol 1992;19:1342-7.
23. Choy EH, Chikanza IC, Kingsley GH, et al. Treatment of rheumatoid arthritis with single dose or weekly pulses of chimaeric anti-CD4 monoclonal antibody. Scand J Immunol 1992;36:291-8.
24. Choy EH, Pitzalis C, Bijl JA, et al. The amount of anti-CD4 monoclonal antibody (Mab) entering the rheumatoid arthritis (RA) joint may determine clinical efficacy [Abstract]. Arthritis Rheum 1993;36:S39.
25. David CS. Genes for MHC, TCR and MIs determine susceptibility to collagen induced arthritis. Acta Pathol Microbiol Immunol Scand 1990;98:575-84.
26. Moder KG, Luthra HS, Kubo R, et al. Prevention of collagen induced arthritis in mice by treatment with an antibody directed against the T cell receptor alpha beta framework. Autoimmunity 1992;11:219-24.
27. Misra R, Venables PJ, Plater-Zyberk C, et al. Anticardiolipin antibodies in infectious mononucleosis react with the membrane of activated lymphocytes. Clin Exp Immunol 1989;75:35-40.
28. Goldschmidt TJ, Jansson L, Holmdahl R. In vivo elimination of T cells expressing specific T-cell receptor V beta chains in mice susceptible to collagen-induced arthritis. Immunology 1990;69:508-14.
29. Paliard X, West SG, Lafferty JA, et al. Evidence for the effects of a superantigen in rheumatoid arthritis. Science 1991;253:325-9.
30. Phadke K, Carlson DG, Gitter BD, et al. Role of interleukin 1 and interleukin 2 in rat and mouse arthritis models. J Immunology 1986;136:4085-91.
31. Hayashida K, Ochi T, Fujimoto M, et al. Bone marrow changes in adjuvant-induced and collagen-induced arthritis: interleukin-1 and interleukin-6 activity and abnormal myelopoiesis. Arthritis Rheum 1992;35:241-5.
32. Killar LM, Dunn CJ. Interleukin-1 potentiates the development of collagen-induced arthritis in mice. Clin Sci 1989;76:535-8.
33. Hom JT, Cole H, Estridge T, et al. Interleukin-1 enhances the development of type II collagen-induced arthritis only in susceptible and not in resistant mice. Clin Immunol Immunopathol 1992;62:56-65.
34. Wooley PH, Whalen JD, Chapman DL, et al. The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice. Arthritis Rheum 1993;36:1305-14.
35. Kresina TF. A contra-IL-2 cytokine derived from mice suppressed for collagen-induced arthritis. Cell Immunol 1990;125:171-82.
36. Spannaus-Martin DJ, Holmdahl R, Kresina TF. Immunotherapy of collagen-induced arthritis by a T-cell antiproliferative molecule. Am J Pathol 1990;137:331-9.
37. Banerjee S, Wei BY, Hillman K, et al. Immunosuppression of collagen-induced arthritis in mice with an anti-IL-2 receptor antibody. J Immunol 1988;141:1150-4.
38. Wooley PH, Banerjee S. Immunotherapy of collagen-induced arthritis with anti-Ia and anti-IL-2R antibodies. In: Kresina T, editor. Monoclonal Antibodies, Cytokines, and Arthritis. New York: Marcel Dekker; 1991. p. 269-87.
39. Takai Y, Seki N, Senoh H, et al. Enhanced production of interleukin-6 in mice with type II collagen-induced arthritis. Arthritis Rheum 1989;32:594-600.
40. Cooper SM, Sriram S, Ranges GE. Suppression of murine collagen-induced arthritis with monoclonal anti-Ia antibodies and augmentation with IFN-gamma. J Immunol 1988;141:1958-62.
41. Williams RO, Williams DG, Feldmann M, et al. Increased limb involvement in murine collagen-induced arthritis following treatment with anti-interferon-gamma. Clin Exp Immunol 1993;92:323-7.
42. Ortmann RA, Shevach EM. Susceptibility to collagen-induced arthritis: cytokine-mediated regulation. Clin Immunol 2001;98:109-18.
43. Guedez YB, Whittington KB, Clayton JL, et al. Genetic ablation of interferon-gamma up-regulates interleukin-1beta expression and enables the elicitation of collagen-induced arthritis in a nonsusceptible mouse strain. Arthritis Rheum 2001;44:2413-24.
44. Keffer J, Probert L, Cazlaris H, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991;10:4025-31.
45. Altomonte L, Zoli A, Mirone L, et al. Serum levels of interleukin-1b, tumour necrosis factor-a and interleukin-2 in rheumatoid arthritis. Correlation with disease activity. Clin Rheumatol 1992;11:202-5.
46. Alvaro-Gracia JM, Zvaifler NJ, Brown CB, et al. Cytokines in chronic inflammatory arthritis. VI. Analysis of the synovial cells involved in granulocyte-macrophage colony-stimulating factor production and gene expression in rheumatoid arthritis and its regulation by IL-1 and tumor necrosis factor-alpha. J Immunol 1991;146:3365-71.
47. Husby G, Williams RC Jr. Synovial localization of tumor necrosis factor in patients with rheumatoid arthritis. J Autoimmun 1988;1:363-71.
48. Brahn E, Peacock DJ, Banquerigo ML, et al. Effects of tumor necrosis factor alpha (TNF-alpha) on collagen arthritis. Lymphokine Cytokine Res 1992;11:253-6.
49. Thorbecke GJ, Shah R, Leu CH, et al. Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc Nat Acad Sci U S A 1992;89:7375-9.
50. Piguet PF, Grau GE, Vesin C, et al. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 1992;77:510-4.
51. Petersen MM, Nielsen PT, Lebech A, et al. Preoperative bone mineral density of the proximal tibia and migration of the tibial component after uncemented total knee arthroplasty. J Arthroplasty 1999;14:77-81.
52. Kuruvilla AP, Shah R, Hochwald GM, et al. Protective effect of transforming growth factor on experimental autoimmune diseases in mice. Proc Natl Acad Sci U S A 1991;88:2918-21.
53. Cooper WO, Fava RA, Gates CA, et al. Acceleration of onset of collagen-induced arthritis by intra-articular injection of tumour necrosis factor or transforming growth factor-beta. Clin Exp Immunol 1992;89:244-50.
54. Skapenko A, Wendler J, Lipsky PE, et al. Altered memory T cell differentiation in patients with early rheumatoid arthritis. J Immunol 1999;163:491-9.
55. Mauri C, Williams RO, Walmsley M, et al. Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis. Eur J Immunol 1996;26:1511-8.
56. Myers LK, Rosloniec EF, Cremer MA, et al. Collagen-induced arthritis, an animal model of autoimmunity. Life Sci 1997;61:1861-78.
57. Boissier MC, Chiocchia G, Bessis N, et al. Biphasic effect of interferon-gamma in murine collagen-induced arthritis. Eur J Immunol 1995;25:1184-90.
58. Parks E, Strieter RM, Lukacs NW, et al. Transient gene transfer of IL-12 regulates chemokine expression and disease severity in experimental arthritis. J Immunol 1998;160:4615-9.
59. Joosten LA, Lubberts E, Durez P, et al. Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis: protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction. Arthritis Rheum 1997;40:249-60.
60. Bessis N, Boissier MC, Ferrara P, et al. Attenuation of collagen-induced arthritis in mice by treatment with vector cells engineered to secrete interleukin-13. Eur J Immunol 1996;26:2399-403.
61. Dolhain RJ, van der Heiden AN, ter Haar NT, et al. Shift toward T lymphocytes with a T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis. Arthritis Rheum 1996;39:1961-9.
62. Chen Y, Rosloniec E, Goral MI, et al. Redirection of T cell effector function in vivo and enhanced collagen-induced arthritis mediated by an IL-2R beta/IL-4R alpha chimeric cytokine receptor transgene. J Immunol 2001;166:4163-9.
63. Inada S, Yoshino S, Haque MA, et al. Clonal anergy is a potent mechanism of oral tolerance in the suppression of acute antigen-induced arthritis in rats by oral administration of the inducing antigen. Cell Immunol 1997;175:67-75.
64. Staines NA, Wooley PH. Collagen arthritis-what can it teach us? Br J Rheumatol 1994;33:798-807.
65. Thompson SJ, Thompson HS, Harper N, et al. Prevention of pristane-induced arthritis by the oral administration of type II collagen. Immunology 1993;79:152-7.
66. Zhang ZJ, Lee CSY, Lider O, et al. Suppression of adjuvant arthritis in Lewis rats by oral administration of type II collagen. J Immunol 1990;145:2489-93.
67. Higuchi K, Kweon MN, Fujihashi K, et al. Comparison of nasal and oral tolerance for the prevention of collagen induced murine arthritis. J Rheumatol 2000;27:1038-44.
68. Barnett ML, Kremer JM, St Clair EW, et al. Treatment of rheumatoid arthritis with oral type II collagen: results of a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 1998;41:290-7.
69. Thorbecke GJ, Schwarcz R, Leu J, et al. Modulation by cytokines of induction of oral tolerance to type II collagen. Arthritis Rheum 1999;42:110-8.
70. Robbins PD, Evans CH, Chernajovsky Y. Gene therapy for rheumatoid arthritis. Springer Semin Immunopathol 1998;20:197-209.
71. Bandara G, Mueller GM, Galea-Lauri J, et al. Intraarticular expression of biologically active interleukin 1-receptor-antagonist protein by ex vivo gene transfer. Proc Nat Acad Sci U S A 1993;90:10764-8.
72. Le CH, Nicolson AG, Morales A, et al. Suppression of collagen-induced arthritis through adenovirus-mediated transfer of a modified tumor necrosis factor alpha receptor gene. Arthritis Rheum 1997;40:1662-9.
73. Quattrocchi E, Walmsley M, Browne K, et al. Paradoxical effects of adenovirus-mediated blockade of TNF activity in murine collagen-induced arthritis. J Immunol 1999;163:1000-9.
74. Lubberts E, Joosten LA, van Den BL, et al. Adenoviral vector-mediated overexpression of IL-4 in the knee joint of mice with collagen-induced arthritis prevents cartilage destruction. J Immunol 1999;163:4546-56.
75. Whalen JD, Lechman EL, Carlos CA, et al. Adenoviral transfer of the viral IL-10 gene periarticularly to mouse paws suppresses development of collagen-induced arthritis in both injected and uninjected paws. J Immunol 1999;162:3625-32.
76. Nakajima A, Seroogy CM, Sandora MR, et al. Antigen-specific T cell-mediated gene therapy in collagen-induced arthritis. J Clin Invest 2001;107:1293-301.
77. Morita Y, Yang J, Gupta R, et al. Dendritic cells genetically engineered express IL-4 inhibit murine collagen-induced arthritis. J Clin Invest 2001;107:1275-84.
78. Apparailly F, Noel D, Millet V, et al. Paradoxical effects of tissue inhibitor of metalloproteinases 1 gene transfer in collagen-induced arthritis. Arthritis Rheum 2001;44:1444-54.